ArticleBMC cardiovascular disorders2025
Runx1 drives cardiac fibrosis and heart failure through epigenetic activation of myofibroblasts in pressure overload-induced cardiac remodeling.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Decoding fibroblast activation: Transcriptional networks in hepatic stellate cells and across fibrotic organs (Review).International journal of molecular medicine · 2026Review
- SOX2-OT serves as a diagnostic and prognostic biomarker for hypertensive left ventricular hypertrophy by targeting miR-30d-5p.Molecular and cellular biochemistry · 2026Article
- Article
- The critical role of the RUNX1/NF-κB transcriptional complex-mediated PVAT-VSMC axis in aortic dissection.Journal of cardiothoracic surgery · 2026Review
- YAP/TAZ inhibition refines TGF-β signaling to prevent laryngeal fibrosis.bioRxiv : the preprint server for biology · 2026Article
- Fibroblast RUNX1 Induces Maladaptive Post-Myocardial Infarction Remodeling.JACC. Basic to translational science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundHeart failure (HF) is often accompanied by cardiac fibrosis, a pathological process driven by activated cardiac fibroblasts (CFs) transitioning to a myofibroblast phenotype. The Runt-related transcription factor 1 (Runx1) has been implicated in various fibrotic diseases, but its role in cardiac fibrosis and HF progression remains unclear. This study aimed to elucidate the role of Runx1 in CF activation, cardiac fibrosis, and HF development.
methodsHF was induced in mice using transverse aortic constriction (TAC). Runx1 expression was assessed in failing hearts via Western blot and qPCR, with immunostaining to localize Runx1 in CFs. In vitro, CFs were treated with TGF-β, and Runx1 knockdown was achieved using siRNA or adenoviral-mediated deletion. Myofibroblast-specific Runx1 knockout mice (PostnCre, Runx1F/F) were used to investigate the in vivo effects of Runx1 on cardiac function, fibrosis, and hypertrophy post-TAC. Chromatin immunoprecipitation (ChIP) and luciferase assays were conducted to evaluate Runx1's regulation of Postn transcription.
resultsTAC-induced HF was associated with significant upregulation of Runx1 protein and mRNA levels, particularly in CFs. In vitro, Runx1 knockdown suppressed TGF-β-induced markers of CF activation, including α-smooth muscle actin (α-SMA), periostin (Postn), and collagen type I (Col1a1), and reduced CF migration and proliferation. PostnCre-Runx1F/F mice exhibited improved cardiac function, reduced hypertrophy, and decreased fibrosis compared to control mice post-TAC. Mechanistically, Runx1 was found to bind the Postn promoter and recruit the transcriptional coactivator P300, enhancing histone acetylation and promoting Postn transcription.
conclusionsRunx1 plays a pivotal role in cardiac fibroblast activation and fibrosis, likely through epigenetic regulation of Postn expression, thereby driving heart failure progression. Targeting Runx1 may represent a promising therapeutic strategy for heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.